Antibodies against human CD45RA protein, antibody conjugates and their applications

By developing specific anti-human CD45RA protein antibodies, the problem of insufficient specificity and affinity of existing antibodies in live cell flow cytometry detection is solved, and high accuracy and sensitivity detection of CD45RA protein is achieved, which is suitable for flow cytometry analysis.

CN118620078BActive Publication Date: 2024-11-19WUHAN AIBO TAIKE BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410915325.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-19
Estimated Expiration
2044-07-09

AI Technical Summary

Technical Problem

The specificity, affinity and/or anti-interference ability of existing anti-human CD45RA protein antibodies is difficult to use in flow cytometry in living cells, especially because the content of the target antigen CD45RA is low and the number of interference factors is high, resulting in non-specific binding.

Method used

An antibody against human CD45RA protein, which includes specific light and heavy chain variable region amino acid sequences, is developed, which can specifically recognize and bind human CD45RA protein and has no cross-reactivity with isotype proteins, for use in the field of immunologic detection , including enzyme-linked immunosorbent assay, enzyme immunoassay, immunofluorescence and flow cytometry.

Benefits of technology

It significantly improves the accuracy, sensitivity and reliability of the CD45RA protein in immunoassays, provides high specific antibodies that meet flow cytometry analysis applications, can effectively resist cell component interference, and is suitable for immune detection fields such as flow cytometry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118620078B_ABST
    Figure CN118620078B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of antibody preparation, and in particular to antibodies, antibody conjugates and applications thereof against human CD45RA proteins. The amino acid sequences of CDR1-3 on the light chain variable region of the antibody are shown in SEQ ID NO.3-5, respectively, and the amino acid sequences of CDR1-3 on the heavy chain variable region are shown in SEQ ID NO.8-10, respectively. The antibodies with the above CDR sequences provided by the present invention can specifically recognize the recombinant CD45RA protein expressed by genetic engineering and the natural CD45RA protein expressed in cells or tissues, and have no cross-reaction with isotype proteins, have good specificity and high affinity, can effectively resist interference from cellular components, significantly improve the accuracy, sensitivity and reliability of immunodetection of CD45RA protein, and have broad application prospects in immunodetection fields such as flow cytometry.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of antibody preparation, and in particular to an antibody against human CD45RA protein, an antibody conjugate and applications thereof. Background Art

[0002] CD45, also known as C-type protein tyrosine phosphatase receptor (PTPRC), is a leukocyte common antigen (LCA), a type I transmembrane protein, expressed in all hematopoietic stem cell lineage cells except mature red blood cells and platelets, including T cells, B cells, natural killer cells and macrophages, and is an important regulator of T and B cell antigen receptor-mediated activation. The cytoplasmic segment of CD45 has the function of protein tyrosine phosphatase, which can dephosphorylate tyrosine on the substrate and activate it. It is a key molecule for signal transduction on the cell membrane and is of great significance in the development and maturation of lymphocytes, functional regulation and signal transduction.

[0003] CD45 is composed of a class of transmembrane proteins with similar structures and large molecular weight. Multiple CD45 subtypes can be produced through the selective splicing of exons 4 (A), 5 (B) and 6 (C) in the extracellular domain. The isotype that only expresses exon A is called CD45RA, the isotype that only expresses exon B is called CD45RB, the isotype that only expresses exon C is called CD45RC, and the isotype that lacks all three exons is called CD45RO. The changes in CD45 subtypes change with the activation of T cells and affect intracellular signal transduction. Therefore, the distribution of CD45 subtypes is often used as a classification marker for certain T cell subsets. The expression of different CD45 subtypes by T lymphocytes has a certain relationship with their functional differences. Usually, CD45RO is expressed in memory T cells, and CD45RA is expressed in naive T cells. Memory helper T cells produce cytokines and other effector factors under antigen stimulation to assist B cells in producing antibodies. Naive T cells proliferate under antigen stimulation, and the expression of CD45RA on their surface decreases and turns into CD45RO to enhance the immune response. Therefore, CD45RA / CD45RO, as an important subtype of CD45, is also regarded as an ideal marker to distinguish between naive T cells and memory T cells. It plays a key role in immune response, viral infection and autoimmune diseases.

[0004] CD45RA + and CD45RO +T cells are different in phenotype and function, and understanding the changes in their subgroups helps to understand the pathogenesis, clinical status and prognosis of many diseases. It has been found that the expression of CD45RA changes significantly in diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, allergic purpura, myeloid leukemia, herpes zoster, bronchial asthma, anemia, colorectal cancer, and gastric cancer. It can be used as an important basis for clinical diagnosis and can also be used to detect CD4 + CD45RA + The number of cells is used to evaluate the therapeutic effect of highly active antiretroviral therapy (HAART) in the course of AIDS. It can be seen that the detection of CD45RA expression level has important scientific research value and clinical significance.

[0005] In the field of live cell detection, flow cytometry (FC) is mainly used to identify cell subpopulations, and the key lies in the development of anti-CD45RA antibodies. Currently, the development of CD45RA antibodies on the market mainly meets the detection applications of immunoblotting (WB), immunohistochemistry (IHC), etc., and there are few antibodies that meet the application of FC analysis. This is because the content of the target antigen CD45RA is low and there are many interfering factors during the FC detection process, and there are many isotypes of proteins. The low specificity and / or affinity of the antibody can easily lead to non-specific binding. Therefore, there are few monoclonal antibodies on the market that meet the application of FC analysis. Therefore, it is of great significance to develop a highly specific CD45RA antibody that can meet the application scenarios of flow cytometry analysis. Summary of the invention

[0006] In view of the problems that the anti-human CD45RA protein antibodies in the prior art have poor specificity, affinity and / or anti-interference ability and are difficult to be used for live cell detection, especially live cell flow cytometry detection, the present invention provides antibodies against human CD45RA protein and antibody conjugates thereof, and further provides the use of the antibodies or antibody conjugates in the preparation of human CD45RA protein immunoassay reagents and / or kits and related immunoassay reagents and / or kits. The antibodies provided by the present invention can specifically recognize and bind to human CD45RA protein, have high affinity with the target, have no cross-reaction to other CD45 protein subtypes, and can be applied to the field of immunological detection. To achieve the aforementioned purpose, the present invention is specifically implemented through the following technical solutions:

[0007] In a first aspect, the present invention provides an antibody against human CD45RA protein, comprising a light chain variable region and a heavy chain variable region, wherein the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the light chain variable region are shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively; and the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.

[0008] Furthermore, the amino acid sequence of the light chain variable region is shown as SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.7.

[0009] Furthermore, the antibody also includes a light chain constant region and a heavy chain constant region; wherein the light chain constant region and the light chain variable region constitute a complete light chain, and the amino acid sequence of the light chain is shown in SEQ ID NO.1; the heavy chain constant region and the heavy chain variable region constitute a complete heavy chain, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6.

[0010] Furthermore, the antibody is a full-length antibody or an antigen-binding region thereof; the antigen-binding region is selected from the group consisting of a Fab fragment, a F(ab) 2 Fragment, Fv fragment, (Fv) 2 Fragments, scFv fragments and sc(Fv) 2 At least one of the fragments.

[0011] The second aspect of the present invention provides an antibody conjugate comprising the above-mentioned anti-human CD45RA protein antibody and a detection label connected to the antibody.

[0012] The third aspect of the present invention provides a nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule, or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the antibody against human CD45RA protein as described above.

[0013] Furthermore, the nucleic acid sequence of the antibody light chain variable region is as shown in SEQ ID NO.16 or a sequence complementary thereto, and the nucleic acid sequence of the heavy chain variable region is as shown in SEQ ID NO.18 or a sequence complementary thereto.

[0014] Furthermore, the nucleic acid sequence of the antibody light chain is as shown in SEQ ID NO.15 or a sequence complementary thereto, and the nucleic acid sequence of the heavy chain is as shown in SEQ ID NO.17 or a sequence complementary thereto.

[0015] The fourth aspect of the present invention provides the use of the above-mentioned anti-human CD45RA protein antibody or antibody conjugate in the preparation of a human CD45RA protein immunoassay reagent and / or kit.

[0016] A fifth aspect of the present invention provides a human CD45RA protein immunoassay reagent and / or kit, wherein the detection reagent and / or kit comprises the anti-human CD45RA protein antibody or antibody conjugate as described above.

[0017] Furthermore, the immunodetection method includes at least one of enzyme immunoassay, enzyme-linked immunosorbent assay, immunofluorescence, immunoblotting and flow cytometry.

[0018] The advantages and positive effects of the present invention are:

[0019] The antibody provided by the present invention having the above-mentioned CDR sequence can specifically recognize the recombinant CD45RA protein expressed by genetic engineering and the natural CD45RA protein expressed in cells or tissues, and has no cross-reaction with the same type of protein, has good specificity and high affinity, can effectively resist the interference of cellular components, and significantly improves the accuracy, sensitivity and reliability of immunodetection of CD45RA protein, and has broad application prospects in the field of immunodetection such as flow cytometry. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0021] Figure 1 This is a graph showing the result of detecting the rabbit immune serum titer by enzyme-linked immunosorbent assay in Example 1 of the present invention;

[0022] Figure 2 This is a result diagram of detecting the binding of rabbit immune serum to positive Jurkat cells by flow cytometry in Example 1 of the present invention, wherein, from left to right, the serum dilutions are 1:500, 1:1000 and 1:2000 respectively;

[0023] Figure 3 This is a result diagram of detecting the binding of rabbit immune serum to negative cells 293T by flow cytometry in Example 1 of the present invention, wherein, from left to right, the serum dilutions are 1:500, 1:1000 and 1:2000 respectively;

[0024] Figure 4A map of the mammalian expression vector pRB322 used to construct an anti-human CD45RA protein antibody in Example 1 of the present invention, from left to right, respectively, the vectors carrying the antibody light chain constant region and heavy chain constant region in advance;

[0025] Figure 5 This is a result diagram of the detection of the binding of anti-human CD45RA protein antibody to positive cells Daudi by flow cytometry in Example 3 of the present invention, wherein the fluorescent marker is ABflo 488, the left picture shows negative cells 293T, and the right picture shows positive cells Daudi;

[0026] Figure 6 This is a graph showing the results of detecting the binding of anti-human CD45RA protein antibodies to positive Jurkat cells by flow cytometry in Example 3 of the present invention, wherein the fluorescent marker is ABflo 647, the left picture shows negative cells 293T, and the right picture shows positive cells Jurkat. DETAILED DESCRIPTION

[0027] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0028] Based on the information contained in the present invention, it is easy for those skilled in the art to make various changes to the precise description of the present invention without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the defined processes, properties or components, because these embodiments and other descriptions are only for the purpose of illustrating specific aspects of the present invention. In fact, various changes that a person skilled in the art or related fields can obviously make to the embodiments of the present invention are covered within the scope of the appended claims.

[0029] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers and other numerical values ​​used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties to be obtained. Each numerical parameter should at least be regarded as obtained according to the reported significant figures and by conventional rounding methods.

[0030] In addition, it should be noted that, unless otherwise defined, in the context of the present invention, the scientific and technical terms used should have the meanings commonly understood by those of ordinary skill in the art.

[0031] The meaning of the terms "include", "comprising", "containing", "having" and the like is non-restrictive, that is, other steps and other ingredients that do not affect the result may be added. The term "and / or" should be regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" is regarded as including the following situations: (i) A, (ii) B and (iii) A and B.

[0032] The terms "rabbit monoclonal antibody", "monoclonal antibody", "rabbit antibody" and "rabbit monoclonal antibody" and other similar terms have the same meaning and, unless otherwise specified, refer to antibodies that specifically bind to human CD45RA. The modifier "rabbit" indicates that the complementarity determining region (CDR) of the antibody is derived from a rabbit immunoglobulin sequence.

[0033] An antibody is an immunoglobulin molecule that can specifically bind to a target antigen or epitope through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. In the present invention, the term "antibody" should be interpreted in the broadest sense and includes different antibody structures, including but not limited to so-called full-length antibodies, antibody fragments, and their genetic or chemical modifications, as long as they exhibit the desired antigen-binding activity.

[0034] A typical antibody molecule (full-length antibody) consists of two identical light chains (L) and two identical heavy chains (H). Light chains can be divided into two types, namely κ chain and λ chain; heavy chains can be classified into five types, namely μ, δ, γ, α and ε chains, and antibodies are defined as IgM, IgD, IgG, IgA and IgE, respectively. The amino acid sequences near the N-terminus of the heavy and light chains vary greatly, while the amino acid sequences of other parts are relatively constant. The regions near the N-terminus of the light and heavy chains where the amino acid sequences vary greatly are called variable regions (V), and the regions near the C-terminus where the amino acid sequences are relatively stable are called constant regions (C). The heavy chain variable region (VH) and the light chain variable region (VL) are usually the most variable parts of the antibody and contain antigen recognition sites. The VH and VL regions can be further subdivided into hypervariable regions (HVR) and framework regions (FR). The hypervariable regions are also called complementarity determining regions (CDRs), which are ring-shaped structures. The heavy chain CDR and the light chain CDR are closely together and cooperate with each other through the FR region, forming a surface that can complement the three-dimensional structure of the target antigen or epitope, which determines the specificity of the antibody and is the site where the antibody recognizes and binds to the antigen. The FR region is the more conservative part of VH and VL. They are generally in a β-folded configuration and are connected by three CDRs that form a connecting loop. Each VH and VL is usually composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0035] CDRs and FRs can be identified according to the Kabat definition, the Chothia definition, the accumulation of both the Kabat definition and the Chothia definition, the AbM definition, the contact definition, the IMGT unique numbering definition and / or the conformational definition, or any CDR determination method known in the art. As used herein, the Kabat numbering system is used to define.

[0036] The light chain constant region (CL) and the heavy chain constant region (CH) are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity of antibodies. The length of CL of different types of Ig (κ or λ) is basically the same, but the length of CH of different classes of Ig is different, such as IgG, IgA and IgD include CH1, CH2 and CH3, while IgM and IgE include CH1, CH2, CH3 and CH4. The amino acid sequences of the heavy chain and light chain constant regions of antibodies are well known in the art.

[0037] A full-length antibody is the most complete antibody molecular structure and has a typical Y-shaped molecular structure. Therefore, in the context of the present invention, "full-length antibody", "complete antibody" and "Y-shaped antibody" have the same meaning and can be used interchangeably.

[0038] Antibody fragments are one or more parts or fragments of a full-length antibody, which essentially retain the same biological function or activity as the full-length form. Specifically, antibody fragments at least include the same CDR region as the full-length antibody, and more preferably have the same variable region, thereby retaining complete antigen recognition and binding sites, and can bind to the same antigen as the full-length antibody, especially to the same epitope. In typical examples, antibody fragments include: Fab, F(ab) 2 , Fab', F(ab') 2 、Fv、(Fv) 2 , scFv, sc(Fv) 2 These antibody fragments can be obtained by conventional techniques in the art.

[0039] (i) Fab: Antigen-binding fragment (Fab) is a monovalent fragment consisting of a complete light chain (variable region and constant region) and a portion of the heavy chain (variable region and first constant region). Fab and F(ab') can be obtained by proteolytic cleavage of the full-length antibody. 2 , Fab' and other fragments. For example, under the action of papain, IgG can be degraded into two Fab fragments and one Fc fragment; under the action of pepsin, IgG can be degraded into one F(ab') 2 fragment and a pFc' fragment. F(ab') 2 The fragment is further reduced to form two Fab' fragments. Since Fab has an antigen binding region and a partial constant region, it not only has the same antibody-antigen affinity and excellent tissue penetration as scFv, but also has a more stable structure.

[0040] (ii) F(ab) 2 : A bivalent fragment consisting of two Fabs connected by a disulfide bridge in the hinge region.

[0041] (iii) Fv: The variable fragment (Fv) is located at the N-terminus of the antibody Fab fragment, contains only the variable region, and is composed of the variable regions of a light chain and a heavy chain. It is a dimer of VH and VL non-covalently bound (VH-VL dimer). The three CDRs of each variable region interact with each other to form an antigen binding site on the surface of the VH-VL dimer, which has the ability to recognize and bind to antigens, although the affinity is lower than that of the intact antibody.

[0042] (iv)(Fv) 2: Consists of two Fv fragments covalently linked together.

[0043] (v) scFv: Single-chain variable fragment (scFv) is an Fv fragment composed of a single polypeptide chain, which is composed of a heavy chain variable region (VH) and a light chain variable region (VL) connected by a flexible linker (generally composed of 10-25 amino acids), which retains the binding specificity of the original antibody to the antigen. The linker in the present invention is not particularly limited as long as it does not hinder the expression of the antibody variable regions connected to its two ends. Compared with full-length antibodies, scFv has the characteristics of small molecular weight, so it has higher penetration and lower immune side effects.

[0044] (vi)sc(Fv) 2 The fragment is composed of two heavy chain variable regions and two light chain variable regions connected by a linker or the like.

[0045] In some embodiments, the full-length sequence of the antibody or antibody fragment of the present invention may include a complementary determining region (CDR) and a framework region (FR) from a rabbit immunoglobulin sequence. In other embodiments, the antibody may include amino acid residues encoded by non-rabbit immunoglobulin sequences, for example, humanized antibodies, chimeric antibodies, etc., to reduce the body's rejection reaction while maintaining the required specificity and affinity. The term "chimeric antibody" refers to a portion of an antibody derived from a specific source or species, while the rest is derived from a different source or species. The term "humanized antibody" is a chimeric antibody of a non-human antibody such as a rabbit antibody's CDR region and a mouse FR region. In some cases, the variable region of a non-human antibody is combined with a constant region of a human antibody, such as a mouse-rabbit chimeric antibody; in other cases, the CDR region of a non-human antibody is combined with a FR region and a constant region derived from a human antibody sequence, that is, the CDR region of a non-human antibody is grafted onto a mouse antibody framework (FR) sequence, and this framework sequence is derived from a single or multiple other mouse antibody variable region framework sequences. In the present invention, the CDR region in the chimeric antibody or humanized antibody is derived from a rabbit-derived CDR region.

[0046] The terms "monoclonal antibody" or "single antibody" and the like are used interchangeably and refer to a homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for a small amount of mutations and / or post-translational modifications (e.g., isomerization, amidation) that may occur naturally. "Monoclonal antibodies" are highly specific and exhibit a single binding specificity and affinity for the same or substantially identical epitopes on an antigen. The modifier "monoclonal" indicates that the antibody is obtained from a substantially homogeneous antibody population and should not be construed as limiting the source or preparation method of the antibody. The antibody can be prepared by a variety of methods, including but not limited to hybridoma methods, phage display methods, yeast display methods, recombinant DNA methods, single cell screening, or single cell sequencing methods.

[0047] The term "specific binding" is a well-known term in the art, and a molecule exhibits "specific binding" if it reacts with a specific target antigen or epitope more frequently, more rapidly, longer lastingly, and / or with greater affinity than with other target antigens or epitopes. "Specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding.

[0048] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.

[0049] An embodiment of the present invention provides an antibody against human CD45RA protein, comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region each comprise three complementary determining regions (CDRs), respectively named CDR1, CDR2 and CDR3, wherein the amino acid sequences of complementary determining region 1 (CDR1), complementary determining region 2 (CDR2) and complementary determining region 3 (CDR3) on the light chain variable region are shown in SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively; the amino acid sequences of complementary determining region 1 (CDR1), complementary determining region 2 (CDR2) and complementary determining region 3 (CDR3) on the heavy chain variable region are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.

[0050] The anti-human CD45RA protein antibody with the above CDR sequence provided by the present invention can specifically recognize the recombinant CD45RA protein expressed by genetic engineering and the natural CD45RA protein expressed on cells. The reactivity of the antibody to the recombinant CD45RA protein and its isotype protein is detected by enzyme-linked immunosorbent assay. The antibody only recognizes and binds to the CD45RA protein and has no cross-reaction with the isotype protein; further detected by flow cytometry, the antibody of the present invention has obvious fluorescence transition and single signal intensity on positive cells expressing CD45RA protein, but no signal in negative cells. The above results prove that the antibody has good specificity and high affinity for CD45RA protein, can effectively resist interference from cell components, significantly improves the accuracy, sensitivity and reliability of immunodetection of CD45RA protein, and has broad application prospects in immunodetection fields such as flow cytometry.

[0051] Optionally, the light chain variable region and the heavy chain variable region each include four framework regions (FRs), and the four FRs and three CDRs are arranged alternately in sequence to form a variable region. The amino acid sequence of the light chain variable region (VL) of the antibody of the present invention is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.7.

[0052] Optionally, the antibody of the present invention further comprises a light chain constant region and a heavy chain constant region, CL and VL constitute a complete light chain (FL), and CH and VH constitute a complete heavy chain (FH). The constant region of an antibody can usually be obtained by public query, such as: searching for rabbit IgG gamma C reign to obtain CH through the IMGT online database (www.imgt.org), and searching for rabbit IgG Kappa C reign to obtain CL. Specifically, the amino acid sequence of the antibody light chain is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6.

[0053] Optionally, the first antibody and / or the second antibody is a full-length antibody (having a typical Y-shaped molecular structure) or an antigen binding region of the full-length antibody; the antigen binding region refers to a polypeptide that substantially retains the same biological function or activity as the full-length form of the antibody. Specifically, the antigen binding region includes the CDR region as described above, and more preferably has the variable region as described above, thereby retaining a complete antigen recognition and binding site, and being able to bind to the same antigen as the full-length antibody, especially to the same epitope. Optionally, the antigen binding region is selected from Fab, F(ab) 2 , Fab', F(ab') 2 、Fv、(Fv) 2 , scFv and sc(Fv) 2These antigen-binding regions can be obtained by conventional techniques in the art.

[0054] Another embodiment of the present invention provides an antibody conjugate, comprising the above-mentioned anti-human CD45RA protein antibody, and a detection label connected to the antibody.

[0055] The detection label is used to generate a recognizable signal change to identify the sample to be tested according to the signal change. The detection label includes, but is not limited to: biotin, fluorescent dyes (such as umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride), fluorescent proteins (such as allophycocyanin, phycoerythrin, PerCP and phycocyanin), enzymes (such as alkaline phosphatase, acid phosphatase, β-galactosidase, glucose oxidase, horseradish peroxidase, acetylcholinesterase, avidin), colloidal gold, colored magnetic beads, latex particles, radionuclides, detection antibodies or combinations thereof.

[0056] Another embodiment of the present invention provides a nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule, or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule is used to encode the above-mentioned anti-human CD45RA protein antibody.

[0057] Nucleic acid molecules can be in the form of DNA (such as cDNA or genomic DNA or synthetic DNA) or RNA (such as mRNA or synthetic RNA). DNA can be single-stranded or double-stranded, and can also be a coding strand or a non-coding strand.

[0058] The sequence of the nucleic acid molecule can be derived from the antibody AA sequence by conventional means such as codon coding rules. The full-length sequence of the nucleic acid molecule or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. The obtained nucleic acid molecule is inserted into an expression vector, then introduced into a host cell, and cultured under specific conditions to express the antibody.

[0059] Illustratively, the nucleic acid sequence of the antibody light chain variable region is as shown in SEQ ID NO.16 or a sequence complementary thereto, and the nucleic acid sequence of the heavy chain variable region is as shown in SEQ ID NO.18 or a sequence complementary thereto.

[0060] Illustratively, the nucleic acid sequence of the antibody light chain is as shown in SEQ ID NO.15 or a sequence complementary thereto, and the nucleic acid sequence of the heavy chain is as shown in SEQ ID NO.17 or a sequence complementary thereto.

[0061] Those skilled in the art will appreciate that, due to the degeneracy of the genetic code, nucleic acid molecules other than those exemplified above can also encode the antibodies of the present invention. Therefore, the nucleic acid molecules exemplified above should not be used as a limitation on the scope of protection of the present invention.

[0062] The original vector for constructing the recombinant vector is any conventional vector in the art, as long as it can carry the nucleic acid molecule. Typical vectors include plasmids (such as pBR322, pUC series, pET series, pGEX series), viral vectors, bacteriophages (such as λgt4λB, λ-Charon, λΔz1 and M13), cosmids and mini-chromosomes. The vector can be a cloning vector (i.e., used to transfer nucleic acid molecules to a host and multiply in a host cell) or an expression vector (i.e., containing the necessary genetic elements to allow the nucleic acid molecules inserted into the vector to be expressed in the host cell). The nucleic acid molecules of the present invention can be inserted into a suitable vector to form a cloning vector or an expression vector carrying the nucleic acid molecule. This is a well-known technique in the art and will not be described in detail herein.

[0063] The nucleic acid molecules encoding the antibodies FL and FH of the present invention can be inserted into two vectors, respectively, which can be introduced into the same or different host cells. When the heavy chain and the light chain are expressed in different host cells, each chain can be separated from the host cell expressing it, and the separated heavy chain and light chain are mixed and incubated under suitable conditions to form antibodies. In other embodiments, the nucleic acid molecules of antibodies FL and FH can also be cloned into a vector, and each nucleic acid sequence is connected to a suitable promoter downstream; for example, each nucleic acid sequence encoding the heavy chain and the light chain can be operably connected to different promoters, or the nucleic acid sequence encoding the heavy chain and the light chain can be operably connected to a single promoter, so that both the heavy chain and the light chain can be expressed by the same promoter. The choice of expression vector / promoter depends on the type of host cell used to produce the antibody.

[0064] The recombinant vector is transfected or transformed into the host cell using conventional techniques. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA are harvested after the exponential growth phase and treated with CaCl 2 MgCl 2 treatment; it can also be carried out by microinjection, electroporation or liposome packaging, etc. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation, microinjection, electroporation, liposome packaging or particle bombardment to achieve gene introduction.

[0065] The host cell can be a prokaryotic or eukaryotic cell. Examples of prokaryotic host cells that can be used in the present invention include, but are not limited to, Escherichia coli (e.g., DH5α, JM109, BL21, W3110), Bacillus (e.g., Bacillus subtilis, Bacillus thuringiensis), and Enterobacteriaceae strains (e.g., Salmonella typhimurium, Serratia marcescens), and Pseudomonas. Examples of eukaryotic host cells that can be used for transformation include, but are not limited to, yeast, insect cells, and animal cells, such as Drosophila S2 or Sf9 cells, mammalian CHO, CHO DG44, CHO-S, COS-7, 293 series cells, HepG2, Huh7, 3T3, RIN, MDCK, and HEK293 cell lines. After obtaining a host cell transfected or transformed with a recombinant vector as described above, the antibody can be expressed by culturing under suitable conditions, and then separated to obtain a purified antibody.

[0066] In a preferred embodiment, the recombinant vector is a mammalian expression vector pBR322, and the host cell is a human kidney epithelial cell (293F cell).

[0067] Another embodiment of the present invention provides the use of the above-mentioned anti-human CD45RA protein antibody or antibody conjugate in the preparation of a human CD45RA protein immunoassay reagent and / or kit.

[0068] The advantages of using the anti-human CD45RA protein antibody or antibody conjugate in preparing human CD45RA protein immunoassay reagents and / or kits are the same as the advantages of the anti-human CD45RA protein antibody over the prior art as described above, and will not be repeated here.

[0069] The embodiments of the present invention further provide a human CD45RA protein immunoassay reagent and / or kit, wherein the detection reagent and / or kit comprises the anti-human CD45RA protein antibody or antibody conjugate as described above.

[0070] It should be noted that the antibody of the present invention can be used alone or combined or coupled with a detection label to form an antibody conjugate. In some embodiments, the antibody of the present invention is used as an antigen-binding antibody, which specifically recognizes and binds to the CD45RA protein in the sample to be tested, and then a recognizable signal change is generated by the detection label connected thereto to achieve qualitative or quantitative detection of the CD45RA protein. In other embodiments, the anti-human CD45RA protein antibody (as a primary antibody or capture antibody) is not labeled, and the detection label is coupled to a secondary antibody (as a detection antibody) or other molecules that can bind to the primary antibody. For example, if the anti-human CD45RA protein antibody is a rabbit IgG antibody, then the secondary antibody can be an anti-rabbit IgG antibody, thereby generating a recognizable signal change after the secondary antibody coupled with the detection label specifically binds to the antibody of the present invention, thereby achieving qualitative or quantitative detection.

[0071] The above-mentioned immunoassay methods include, but are not limited to, enzyme immunoassay (EIA), enzyme linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISPOT), immunohistochemistry (IHC), immunofluorescence (IF), Western blot (WB), immunoprecipitation (IP) and flow cytometry (FC). The detection objects include recombinantly expressed CD45RA protein and naturally secreted or expressed CD45RA protein. The detection samples include, but are not limited to, serum, plasma, urine, cell culture fluid and tissue homogenate.

[0072] In a preferred embodiment, the immunoassay method is flow cytometry, and the detection reagent and / or kit is a flow cytometry detection reagent and / or kit.

[0073] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as the conditions described in the Molecular Cloning Laboratory Guide (Fourth Edition) published by Cold Spring Harbor Laboratory, or usually under the conditions recommended by the manufacturer.

[0074] Example 1 Preparation of rabbit monoclonal antibody against human CD45RA protein

[0075] The immunogen used is human recombinant CD45RA protein, and the sequence of Human CD45RA protein 26aa-482aa is constructed into pYURK-Chis vector. The sequence of Human CD45RA protein can be found in Uniprot number P08575-8, and the gene sequence can be found in Uniprot number Gene ID: 5788. The pYURK-Chis vector is transferred into 293F cells, and the recombinant Human CD45RA mature protein 26aa-482aa with biological activity is expressed in 293F cells. The CD45RA protein expression and purification method adopts conventional operations in the art.

[0076] The above immunogen was used to immunize New Zealand white rabbits to obtain immune-enhanced B lymphocytes, and then the monoclonal antibody development technology based on single B lymphocyte screening and culture was used to obtain antibodies against human CD45RA protein. The antibody sequencing work was completed by Jinkairui Biotechnology Co., Ltd. The amino acid (AA) and nucleic acid (DNA) sequences of the antibodies are shown in Table 1, where LCDR1-3 respectively represent the light chain complementary determining regions CDR1-3, and HCDR1-3 respectively represent the heavy chain complementary determining regions CDR1-3.

[0077] Table 1 Sequence information of rabbit monoclonal antibodies in this example

[0078]

[0079]

[0080] 1.1 Animal Immunization

[0081] Four New Zealand white rabbits were immunized with recombinant Human CD45RA protein as immunogen; each rabbit was immunized with 200 μg of immunogen. Before the first immunization, the immunogen was mixed with an equal amount of complete Freund's adjuvant (purchased from Sigma) to make an emulsifier, which was injected subcutaneously at multiple points in the rabbit's abdomen and back; after the first immunization, 100 μg of immunogen was mixed with an equal amount of incomplete Freund's adjuvant (purchased from Sigma) to make an emulsifier every 3 weeks, and injected subcutaneously at multiple points in the rabbit's abdomen and back for two booster immunizations. After three immunizations, rabbit serum samples were collected, and the titer against Human CD45RA was determined by ELISA method after dilution of 1:243000. Rabbits with OD450nm exceeding 0.2 were selected and boosted with 200 μg of immunogen subcutaneously at multiple points. The animals were sacrificed three days later and the spleen was taken. The specificity and affinity of serum to positive samples were determined by FC method.

[0082] 1.2. Rabbit immune serum titer linked immunosorbent assay (ELISA) detection

[0083] The immune serum titer was determined by indirect enzyme-linked immunosorbent assay (ELISA), and the specific operations included: 1) Coating Human CD45RA: dilute the recombinant Human CD45RA protein (final concentration of 1 μg / mL) with 1× PBS buffer and add the diluted Human CD45RA protein to a 384-well plate at 25 μL / well. CD45RA protein: After leveling the 384-well plate, briefly centrifuge (stop after rpm reaches 1000) the plate and incubate at 4°C overnight; 2) Blocking: Take out the plate that has been in 4°C overnight, and use a plate washer to add 75 μL of washing buffer (PBS containing 0.05% (v / v) Tween-20) to each well and wash 5 times; then add blocking buffer (PBS containing 1% BSA, 0.5% gelatin and 5% sucrose) at 50 μL / well and incubate at room temperature for 1 hour to block irrelevant binding sites; 3) Scaled dilution and sample loading of the serum to be tested: Repeat 2) to wash the plate, and scale dilution the serum to be tested in a 96-well plate. Use dilution buffer (PBS containing 1% BSA) to dilute the serum three times starting from 1:1000, for a total of 8 scales, and the dilution ratio can be adjusted according to the actual situation. Adjust; 4) Secondary antibody incubation: Repeat 2) plate washing process to clean the well plate, dilute horseradish peroxidase (HRP)-coupled goat anti-rabbit IgG (purchased from Jackson, catalog number 111-035-045) with dilution buffer, the dilution ratio is 1:5000, add the diluted goat anti-rabbit IgG-HRP to the plate at 25 μL / well to bind the target protein in the plate, and incubate at room temperature in the dark for 1 hour; 5) Termination of reaction and color development: Repeat 2) plate washing process to clean the well plate, add TMB at 100 μL / well for color development, incubate at 37°C in the dark for 10 minutes, add 0.5 M oxalic acid solution at 100 μL / well to terminate the reaction, measure the absorption value at 450nm, use pre-immune rabbit serum as negative control, and judge the titer of the immune serum by the ratio of the measured value to the control value ≥2.1.

[0084] Serum titer test results are shown in Figure 1 It can be seen that after the third immunization and the fourth booster immunization, a stronger immune response was produced in the rabbits, and the titer of neutralizing antibodies was higher.

[0085] 1.3. Flow cytometry (FC) detection of rabbit immune serum

[0086] The specificity of immune serum and cell samples to be tested was determined by flow cytometry (FC), which included the following steps: 1) Disinfection: UV irradiation disinfection of the clean bench for 15-20 min, turning on the fan for 5 min, and preparing for sterile work; 2) Cell viability detection: Collect and wash the cells to be tested, determine the total number of cells, check whether the cell viability is around 95% and not less than 90%, and resuspend the cells in 1× PBS solution to about 3×10 6 -5×10 6cells / mL, distribute the cells into a 96-well V-shaped plate, 50 μL per well; 3) Primary antibody incubation: distribute 50 μL of the immune serum diluted with 1×Stain buffer (PBS solution containing 0.5% BSA, BSA purchased from Biofrox, catalog number 4240GR500) into a 96-well V-shaped plate per well, resuspend the cells in each well, and mix; for the negative control, add an equal volume of Stain buffer, resuspend the cells in each well, and mix; wrap the 96-well V-shaped plate with aluminum foil, and gently mix on a microplate shaker for 30 minutes; centrifuge at 400g for 5 minutes, discard the supernatant, and wash twice with Stain buffer; 4) Secondary antibody incubation: distribute 100 μL of Fluorescein (FITC) AffiniPure F(ab')2Fragment Goat Anti-Rabbit diluted 1:200 with Stain buffer per well. IgG (purchased from Jackson, Cat#111-096-046) fluorescent secondary antibody was distributed into a 96-well V-shaped plate, and the cells in each well were resuspended and mixed; wrapped with aluminum foil and gently mixed on a microplate shaker for 30 minutes; washed twice with stain buffer; resuspended the cells in each well with 200 μL FACS buffer and stored in the dark; 5) Flow analysis: analyzed according to the Beckman cytoflex flow analyzer use and maintenance instructions. Isotype control antibody was from ABclonal, Cat#A24173.

[0087] The cell samples included positive cells, human T lymphocyte leukemia cells Jurkat, human B lymphoblastoid cells Daudi, and negative cells, human renal epithelial cells 293T. Positive cells highly expressed CD45RA, while negative cells did not express CD45RA. The FC test results of the diluted rabbit immune serum and positive and negative cells are shown in Figure 2-3 , from left to right, the serum dilutions are 1:500, 1:1000 and 1:2000, respectively. The horizontal axis represents the fluorescence brightness, the vertical axis represents the number of cells, the red curve is the negative control, the blue curve is the isotype control, and the yellow curve is the serum to be tested. It can be seen from the figure that the positive fluorescence signal transition of each serum dilution is good, which confirms that the animal has good immunity and has produced antibodies that can be used for flow cytometry detection. The animal can enter the stage of isolating spleen cells.

[0088] 1.4. Isolation and sorting of B lymphocytes from spleen

[0089] Conventional methods are used to isolate B lymphocytes from the spleen, and antigen-specific B lymphocytes are sorted. For related methods, please refer to the published patents "Method for efficiently isolating single antigen-specific B lymphocytes from spleen cells (publication number: CN110016462A, publication date: 2019-07-16)" and "A B lymphocyte in vitro culture system and application (publication number: CN111518765A, publication date: 2020-08-11)".

[0090] 1.5 Cloning and expression of genes encoding rabbit monoclonal antibodies

[0091] After culture, the supernatant of B cells was used to identify positive clones by antigen-coated ELISA. The cells of positive clones were collected and lysed and then analyzed by Quick-RNA TM RNA was extracted using the MicroPrep kit (purchased from ZYMO, catalog number R1051) and reverse transcribed into cDNA. Using cDNA as a template, the naturally paired rabbit monoclonal antibody light chain variable region (VL) and heavy chain variable region (VH) genes were amplified from the cDNA of the corresponding positive clones by PCR, and several clones were selected for sequencing. The PCR reaction system was as follows: 4 μL cDNA, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 12.5 μL 2×GloriaHiFi (from ABclonal, catalog number RK20717) and 6.5 μL H2O. The PCR amplification program included: 98°C pre-denaturation for 30 s, followed by 40 cycles of 98°C for 10 s, 64°C for 30 s, and 72°C for 30 s, and finally kept at 72°C for 5 min. The resulting reaction solution was stored at 4°C. The sequences of the forward and reverse primers are as follows:

[0092] VL-F: 5'-tgaattcgagctcggtacccatggacacgagggcccccac-3' (see SEQ ID NO. 11);

[0093] VL-R: 5'-cacacacacgatggtgactgttccagttgccacctgatcag-3' (see SEQ ID NO. 12);

[0094] VH-F: 5'-tgaattcgagctcggtacccatggagactgggctgcgctg-3' (see SEQ ID NO. 13);

[0095] VH-R: 5'-gtagcctttgaccaggcagcccagggtcaccgtggagctg-3' (see SEQ ID NO. 14).

[0096] The light chain and heavy chain encoding genes are loaded on the expression vector. The mammalian expression vector pBR322 used pre-carries the rabbit light chain constant region (CL) and heavy chain constant region (CH) sequences. The map of pBR322 is shown in Figure 4 In the figure, pBR322origin and f1origin are replication promoters, Ampcillin is a resistance gene, CMV promoter is a transcription promoter, SV40PAterminator is a tailing signal, Light chain constant is the nucleic acid sequence of CL (left), Heavy chain constant is the nucleic acid sequence of CH (right). CL and CH were obtained by searching the IMGT database (www.imgt.org) for rabbit IgG gamma C reign and rabbit IgG Kappa C reign for CL.

[0097] The antibody variable region gene containing the signal peptide obtained by the above PCR amplification was purified, and the pBR322 plasmid containing rabbit CL and CH was conventionally linearized with NheI and XbaI restriction endonucleases, respectively. The heavy chain variable region and light chain variable region genes were connected to the corresponding plasmids by homologous recombination and sequenced to determine the sequences. The sequencing work was completed by Jin Kairui Biotechnology Co., Ltd., and a rabbit monoclonal antibody against Human CD45RA protein was obtained, named 3B2.

[0098] The signal peptide of this embodiment can adopt the antibody expression signal peptide sequence commonly used in the art, such as the patent "Rabbit monoclonal antibody against human interferon α2 and its application (publication number: CN116063487A, publication date: 2023-05-05)" and the patent "High-affinity Human IL-5 rabbit monoclonal antibody and its application (publication number: CN115819578A, publication date: 2023-03-21)" The upstream of VL has a signal peptide "MDTRAPTQLLGLLLLWLPGATF" (the encoding gene can be ATGGAC ACGAGGGCCCCCACTCAGCTGCTGGGCCTGCTGCTTCTGTGGCTTCCTGGAGCCACCTT T), and the upstream of VH has a signal peptide "METGLRWLLLVAVLKGVQC" (the encoding gene can be ATGGAGACTG GGCTGCGCTGGCTTCTCCTGGTTGCAGTGCTGAAAGGAGTCCAGTGC).

[0099] The constructed expression vectors containing the light chain (FL) gene and the heavy chain (FH) gene were transfected into 293F cells together, and the cells were cultured for 72-96 hours after transfection to obtain the recombinant antibody that recognizes the human CD45RA protein in the culture supernatant. The target antibody 3B2 was purified from the culture supernatant using proteinA affinity gel resin (purchased from Tiandi Renhe, catalog number SA023100). The experimental steps are as follows: the culture supernatant was transferred to a sterile 50mL centrifuge tube, centrifuged at 1000g and 4°C (or room temperature) for 10 minutes, and the supernatant was collected. The pretreated ProteinAAgarose suspension was added to the cell supernatant after centrifugation, and incubated with shaking for 3-4 hours (room temperature) or at 4°C overnight. After the incubation was completed, the ProteinAAgarose suspension was transferred to the adsorption column, centrifuged at room temperature for 1 minute to separate the solid and liquid, and the flow-through was collected. Add 10 times the volume of Protein AAgarose washing buffer and resuspend the particles, centrifuge, collect the washing solution, and repeat the washing twice. Add 1 volume of elution buffer to the adsorption column, centrifuge, obtain the antibody supernatant, put the antibody supernatant into the dialysis bag, dialyze overnight, and obtain the purified antibody 3B2. Use 12% SDS-PAGE gel electrophoresis to verify the purity of the antibody. After the antibody is verified, it is packaged and stored at -20℃ for use. The obtained antibody concentration is 2mg / mL and the purity is greater than 95%.

[0100] Example 2 Detection of Antigen Recognition Specificity of Rabbit Monoclonal Antibody 3B2

[0101] 2.1. Indirect enzyme-linked immunosorbent assay (ELISA) to determine cross-reactivity

[0102] Indirect enzyme-linked immunosorbent assay (ELISA) was used to determine whether 3B2 antibody could specifically recognize CD45RA protein. The specific operation was the same as in Example 1, except that antibody 3B2 was used to replace immune serum, and the antibody was diluted three times starting from 1:1000, with a total of 8 gradients. Human CD45RB (Uniprot No. P08575-9, the preparation method was the same as in Example 1, and the expression segment was 26-463aa) and Human CD45RO (Uniprot No. P08575-4, the preparation method was the same as in Example 1, and the expression segment was 27-120aa) of the isotype protein of Human CD45RA protein were used as negative screening controls, pre-immune rabbit serum was used as a negative control, and other rabbit antibodies that did not recognize CD45RA (from Abclonal, item number A23507) were used as irrelevant controls. NC represents a blank control in which no immune serum / antibody to be tested was added and only buffer (1×PBS containing 1% BSA) was added. The titer detection results are shown in Table 2.

[0103] Table 2 Titer test results of rabbit monoclonal antibody 3B2 in this example

[0104]

[0105] As shown in Table 2, the antibody 3B2 has a high titer only in human CD45RA protein, and no titer is detected in CD45RB and CD45RO, indicating that the antibody specifically recognizes CD45RA, does not recognize and bind to CD45RB and CD45RO, and has high specificity and excellent specificity.

[0106] 2.2. Flow cytometric analysis to determine antibody affinity

[0107] The cell samples of this embodiment include positive samples Jurkat, Daudi and negative samples 293T. Positive samples refer to the corresponding cells or tissues expressing CD45RA protein, and negative samples refer to the corresponding cells or tissues not expressing CD45RA protein. The determination method is shown in Example 1. The primary antibody is the rabbit monoclonal antibody 3B2 of the present invention, the antibody concentration is 0.2 μg / mL, and the fluorescent secondary antibody is ABflo 488 (Fluorescein (FITC) AffiniPure F(ab')2Fragment Goat Anti-Rabbit IgG, Fcγfragment specific, purchased from Jackson, catalog number 115-096-071) or ABflo 647 (Alexa 647AffiniPure Goat Anti-Rabbit IgG, Fcγfragment specific, purchased from Jackson, catalog number 115-605-071), was used to verify the adaptability of the antibody to different fluorescence. The antibody 3B2 of the present invention recognizes CD45RA protein, and the fluorescent secondary antibody recognizes antibody 3B2. By identifying the fluorescence intensity (fluorescence transition) and the percentage of fluorescent cells, the specificity and affinity of the primary antibody can be determined. The results are shown in Figure 5-6 , from left to right are negative cell samples and positive cell samples, Figure 5 Daudi positive cells (fluorescent signal ABflo 488), Figure 6 Jurkat positive cells (fluorescent signal ABflo 647), the horizontal axis represents the fluorescence brightness of 647 or 488, the vertical axis represents the number of cells, the red curve is the negative control, the blue curve is the isotype control, and the yellow curve is the antibody to be tested 3B2.

[0108] The results showed that when antibody 3B2 detected CD45RA protein naturally secreted on the cell surface, the fluorescence transition was good, indicating that the antibody had a high affinity for recognizing the target human CD45RA protein, and there was a unique peak in the positive sample and no background signal in the negative sample, indicating that the antibody had high specificity, high analytical sensitivity, strong anti-interference ability, etc., and had good adaptability to the two fluorescence detection signals of 488 and 647, indicating that the antibody of the present invention can meet the detection characteristics of multiple fluorescence.

[0109] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. An antibody against human CD45RA protein, characterized in that: It comprises a light chain variable region and a heavy chain variable region, wherein the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the light chain variable region are shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively; the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.

2. The anti-human CD45RA protein antibody according to claim 1, characterized in that: The amino acid sequence of the light chain variable region is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.

7.

3. The anti-human CD45RA protein antibody according to claim 2, characterized in that: The antibody also includes a light chain constant region and a heavy chain constant region; wherein the light chain constant region and the light chain variable region constitute a complete light chain, and the amino acid sequence of the light chain is shown in SEQ ID NO.1; the heavy chain constant region and the heavy chain variable region constitute a complete heavy chain, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.

6.

4. The anti-human CD45RA protein antibody according to claim 1, characterized in that: The antibody is a full-length antibody or an antigen-binding region thereof; the antigen-binding region is selected from at least one of a Fab fragment, a F(ab)2 fragment, a Fv fragment, a (Fv)2 fragment, a scFv fragment and a sc(Fv)2 fragment.

5. An antibody conjugate, characterized in that: The method comprises the antibody against human CD45RA protein according to any one of claims 1 to 4, and a detection label connected to the antibody.

6. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the anti-human CD45RA protein antibody according to any one of claims 1 to 4.

7. The nucleic acid molecule according to claim 6, characterized in that The nucleic acid sequence of the antibody light chain variable region is shown as SEQ ID NO.16 or a sequence complementary thereto, and the nucleic acid sequence of the heavy chain variable region is shown as SEQ ID NO.18 or a sequence complementary thereto.

8. The nucleic acid molecule according to claim 7, characterized in that The nucleic acid sequence of the antibody light chain is shown as SEQ ID NO.15 or a sequence complementary thereto, and the nucleic acid sequence of the heavy chain is shown as SEQ ID NO.17 or a sequence complementary thereto.

9. Use of the anti-human CD45RA protein antibody according to any one of claims 1 to 4 or the antibody conjugate according to claim 5 in the preparation of a human CD45RA protein immunoassay reagent and / or kit.

10. A human CD45RA protein immunoassay reagent and / or kit, characterized in that: Comprising the anti-human CD45RA protein antibody according to any one of claims 1 to 4, or the antibody conjugate according to claim 5.